Comparison of clinical, tumour-related and dosimetric factors in grade 0-1, grade 2 and grade 3 radiation pneumonitis after stereotactic body radiotherapy for lung tumours.
about
Complications from Stereotactic Body Radiotherapy for Lung CancerFeasibility study of stereotactic body radiotherapy for peripheral lung tumors with a maximum dose of 100 Gy in five fractions and a heterogeneous dose distribution in the planning target volume.Outcomes of stereotactic body radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules.Impact of Preexisting Interstitial Lung Disease on Acute, Extensive Radiation Pneumonitis: Retrospective Analysis of Patients with Lung Cancer.Stereotactic body radiotherapy with helical TomoTherapy for medically inoperable early stage primary and second-primary non-small-cell lung neoplasm: 1-year outcome and toxicity analysisATM polymorphisms predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy.Predicting risk factors for radiation pneumonitis after stereotactic body radiation therapy for primary or metastatic lung tumours.Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies.A survey of changing trends in modelling radiation lung injury in mice: bringing out the good, the bad, and the uncertain.Risk Factors Associated With Symptomatic Radiation Pneumonitis After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancerClarithromycin mitigates radiation pneumonitis in patients with lung cancer treated with stereotactic body radiotherapy.
P2860
Q26995851-EE3D6E5C-1DA0-4EEA-A5D3-337571AD50A4Q34366580-356CC7B8-F388-4C93-8D12-DB5BAC7F3255Q35124684-D415D7F3-0E75-464C-8A9B-E2C547F62A12Q35804538-70B539A1-0175-4134-948E-0065EDBA075BQ36235528-32CB44F8-25FF-4899-AC50-8789F67319C5Q36674872-9544AD28-5E5A-4484-8C36-2E90CA377A80Q38757792-4847643E-6482-445D-9F78-98F4BAB18886Q38871523-9FC8D212-2E53-4EE3-81B2-28A54D0AB601Q38914828-987D67CD-F3A5-4CA4-9DD3-277CE337F9C5Q39496906-F83C1822-40DE-4086-A38D-5E29D751CBB3Q40496623-479ABC83-0443-48D4-83EB-A1F4948DF4EEQ55315278-A43D6C11-2407-44AF-8AD7-639F97373967
P2860
Comparison of clinical, tumour-related and dosimetric factors in grade 0-1, grade 2 and grade 3 radiation pneumonitis after stereotactic body radiotherapy for lung tumours.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Comparison of clinical, tumour ...... radiotherapy for lung tumours.
@ast
Comparison of clinical, tumour ...... radiotherapy for lung tumours.
@en
type
label
Comparison of clinical, tumour ...... radiotherapy for lung tumours.
@ast
Comparison of clinical, tumour ...... radiotherapy for lung tumours.
@en
prefLabel
Comparison of clinical, tumour ...... radiotherapy for lung tumours.
@ast
Comparison of clinical, tumour ...... radiotherapy for lung tumours.
@en
P2093
P2860
P356
P1476
Comparison of clinical, tumour ...... radiotherapy for lung tumours.
@en
P2093
N Shigematsu
P2860
P304
P356
10.1259/BJR/71635286
P407
P577
2012-01-17T00:00:00Z